# Trump Administration Moves to Reschedule Medical Marijuana | WUNC News > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medical-marijuana-rescheduling-policy-2026/ > **Published:** 2026-04-24T13:07:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:12:14-04:00 > **Clinical Summary:** Explore the 2026 medical marijuana rescheduling policy and its impact on clinical research, patient access, and federal cannabis regulation. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyMedical Cannabis[Fda Regulation](https://cedclinic.com/fda-warning-on-cbd-products/)[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)Patient Access Why This Matters Federal rescheduling of cannabis would fundamentally alter the regulatory landscape for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and patient access. This could enable larger-scale controlled trials and standardized therapeutic products while potentially changing insurance coverage and prescribing frameworks for clinicians. Clinical Summary The reported rescheduling move would shift cannabis from Schedule I (no accepted medical use) to a lower schedule, acknowledging therapeutic potential. This regulatory change could facilitate FDA-approved cannabis medications, enable more rigorous clinical research, and provide clearer guidance for physicians treating patients with cannabis-derived therapeutics. The specific schedule placement will determine research accessibility and clinical implementation pathways. Dr. Caplan’s Take “This represents the most significant regulatory shift in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) in decades. While promising for research and patient access, clinicians should prepare for an evolving landscape of products, dosing standards, and coverage policies that will take years to stabilize.” Clinical Perspective 🧠 Physicians should monitor forthcoming guidance on prescribing protocols and product standards. Patients currently using medical cannabis should maintain their therapeutic regimens while staying informed about potential changes in product availability and insurance coverage. The transition period will likely create uncertainty before establishing clearer clinical frameworks. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20administration%20moves%20to%20reschedule%20medical%20marijuana%20%7C%20WUNC%20News%20%40drcaplan&url=https%3A//www.wunc.org/2026-04-23/trump-administration-moves-to-reschedule-medical-marijuana)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.wunc.org/2026-04-23/trump-administration-moves-to-reschedule-medical-marijuana)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20administration%20moves%20to%20reschedule%20medical%20marijuana%20%7C%20WUNC%20News%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.wunc.org/2026-04-23/trump-administration-moves-to-reschedule-medical-marijuana)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.wunc.org/2026-04-23/trump-administration-moves-to-reschedule-medical-marijuana](https://www.wunc.org/2026-04-23/trump-administration-moves-to-reschedule-medical-marijuana) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What type of cannabis-related topics does this article cover?](#What_type_of_cannabis-related_topics_does_this_article_cover) - [Why is this considered emerging or new information?](#Why_is_this_considered_emerging_or_new_information) - [What should healthcare professionals take away from this article?](#What_should_healthcare_professionals_take_away_from_this_article) - [How does FDA regulation relate to medical cannabis policy?](#How_does_FDA_regulation_relate_to_medical_cannabis_policy) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #76, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What type of cannabis-related topics does this article cover? The article focuses on policy developments, medical cannabis applications, and [FDA regulation](https://cedclinic.com/fda-warning-on-cbd-products/). It also touches on clinical research aspects related to cannabis therapeutics. #### Why is this considered emerging or new information? The article is marked as “New” content from CED Clinic’s cannabis news section. It appears to cover recent policy developments or regulatory changes that have clinical implications for medical cannabis use. #### What should healthcare professionals take away from this article? Healthcare professionals should pay attention to the policy and regulatory developments discussed. These changes may impact how medical cannabis can be prescribed, researched, or implemented in clinical practice. #### How does FDA regulation relate to medical cannabis policy? FDA regulation plays a crucial role in determining how [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/) are approved, monitored, and distributed. Policy changes in this area can significantly affect patient access and clinical implementation of [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Administration Advances Marijuana Rescheduling | Brownstein](https://cedclinic.com/trump-administration-marijuana-rescheduling-2026/) An in-depth look at the Trump administration's efforts to advance marijuana rescheduling and its implications. [Read More](https://cedclinic.com/trump-administration-marijuana-rescheduling-2026/) [Changes could be coming to Oklahoma after medical marijuana reclassified – KOCO](https://cedclinic.com/medical-marijuana-reclassification-impacts-oklahoma/) Explore potential changes in Oklahoma following the reclassification of medical marijuana and what it means for patients. [Learn More](https://cedclinic.com/medical-marijuana-reclassification-impacts-oklahoma/) White House pushes imminent easing of controls on marijuana – The Washington Post Coverage of the White House's push to ease marijuana controls and the expected impact on federal policy. Discover More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).